Quick Summary — APYX scores higher on quality with 6.5/10 vs AMIX's 4.3/10. AMIX trades at $0.41 while APYX trades at $3.96. Both analyzed daily using SEC EDGAR data across 13 institutional models.
APYX scores higher with a 6.5/10 quality rating vs AMIX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $0.41, AMIX trades +41.7% below its Bayesian DCF fair value of $0.59, while APYX at $3.96 trades +73.1% above its estimate of $1.06. APYX shows a wider gap between price and intrinsic value.
AMIX earns a Quality of Company score of 4.3/10 compared to APYX's 6.5/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both AMIX and APYX to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both AMIX and APYX operate in Medical Devices, which has 10 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare AMIX vs APYX differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.